Global Ganja Report

Australia is anticipated to soon legalize cultivation of cannabis for therapeutic and resarch purposes, following a bill introduced to Parliament in Canberra Feb. 10. The proposed legislation, backed by Prime Minister Malcolm Turnbull and leading political parties, would amend the Narcotic Drugs Act of 1967 to allow licensed cultivation and distribution of medical marijuana. The law would also change the Therapeutic Goods Act of 1989 to permit farmers to cultivate and distribute. Introduction of the bill follows recent moves by several Australian states and territories to provide patients participating in clinical trials with access to the herb.

Italy took a step towards relaxing its marijuana policy Jan. 15, when the Council of Ministers approved a measure that removes criminal penalties for researchers who violate terms of their cultivation license, making it punishable only by a light fine. Justice Minister Andrea Orlando was quick to emphasize: "This does not decriminalize those growing weed on their terrace." The Italian military maintains a monopoly on cultivation for medical users, while only a handful of private firms have licenses to cultivate for research purposes. Those caught growing their own without a license still face up to a year in prison and a €4 million fine. But support is growing in parliament for a general decriminalization or even legalization that would extend to personal cultivation. Last July, over 200 lawmakers agreed to provisional text for a legalization bill.

Costa Rica took a step towards becoming the next Latin American country to decriminalize cannabis Jan. 19, when attorney Mario Alberto Cerdas Salazar was cleared of cultivation charges on grounds of individual liberties. Cerdas Salazar was arrested in August at his home in the city of Alajuela in August, after publicly advocating for a personal right to use and cultivation of cannabis for medicinal and gastronomic purposes. He has been held since, charged with "drug trafficking." The Judicial Investigation Organism (OIJ, Costa Rica's answer to the FBI) said they found enough cannabis on the premises to make 5,000 cigarettes. The quantity was also ambiguously put at 170 "plants and leaves of plants." But the OIJ admitted they had no evidence the cannabis was intended for commercial purposes. The judge hearing the case, Carolina Leitón, found: "Yes, marijuana cultivation is illegal; nonetheless, it is not a crime if it is not utilized for sale." 

There is no end to false Internet rumors concerning our favorite herb, and the latest was just called out by those dogged rumor-busters at Snopes. It seems that Britain's Sky News of Jan. 13 reported on a clinical trial of an experimental drug in France that went horribly wrong, leaving one brain-dead and another three with what could be permanent brain damage. A total of 90 were given then new painkiller compound manufactured by the Portuguese pharma firm BIAL in a test overseen by UK-based Biotrial. The original Sky News account (as quoted by Snopes) refered to the compound as "cannabis-based." Currently, it only says that French Health Minister Marisol Touraine "denied reports the drug was based on the compound found in cannabis." But it got around before the text was changed, popping up on e-mail lists and social media.

Pharmaceutical firm Vireo Health of Minneapolis announced Dec. 30 that its medical marijuana has been certified kosher by the Orthodox Union, the body that sets such standards for America's half-million Orthodox Jews. The OU's Kosher Certification program usually stamps its seal of approval on food products. But now Vireo Health, one of five companies licensed to market medical marijuana in New York state, has received the OU's imprimatur for herbal product—a first in the industry. The New York Daily News reports that the OU rabbinical association gave its certification after inspecting the company's facilities and finding that the cannabis is produced according to the laws of kashrut—for example, being entirely free of insects.

Following through on a pledge made last month, Colombian President Juan Manuel Santos on Dec. 22 signed a decree broadly legalizing medical marijuana. The new regulation—making it legal to grow, process, import and export cannabis for medical and scientific use—was hailed by Santos as positioning Colombia "at the forefront in the fight against disease." In a line clearly aimed at placating Washington, he also insisted that "the medicinal use of cannabis does not go counter to our international commitments in the field of drug control."

On Dec. 18, Congress approved a $1.1 trillion dollar spending bill—and in the process approved a provision promising to keep federal law enforcement out of medical marijuana operations in states that have passed acts legalizing them. The provision, known as the Rohrabacher-Farr amendment, was first approved in December of last year. The rider for a second year bars the use of Department of Justice funds "to prevent such States from implementing their own State laws that authorize the use, distribution, possession, or cultivation of medical marijuana."

Philadelphia Inquirer columnist Chris Goldstein got hold of a leaked 45-page internal equity report from high-finance titan Merrill Lynch, wealth management division of Bank of America, looking at the future prospects for America's cannabis industry. Goldstein wrote it up for his occassional series Philly420 Dec. 8 under the title "Merrill Lynch is bullish on marijuana." Goldstein finds: "Carefully researched, it was an interesting peek at how heavy hitters on Wall Street are starting to view the expanding industry."